Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    MIT’s New Tool “SeaSplat” Reveals True Colors of the Ocean in 3D

    May 23, 2025

    GLP-1 and Weight-Loss Drugs May Curb Alcohol Cravings, Study Finds

    May 14, 2025

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    May 9, 2025
    Facebook X (Twitter) Instagram LinkedIn
    • About Us
    • Press Release
    Saturday, May 24
    Facebook X (Twitter) LinkedIn Instagram
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    • Magazines
    • Featured Leaders
    • Technology
      • Big Data
      • Artificial Intelligence
      • Robotics
      • Cloud
      • Cyber Security
      • Storage
      • IoT
      • Blockchain
      • Data Analytics
    • Industry
      • Banking & Finance
      • Construction
      • Digital Marketing
      • Economy
      • Education
      • EV Industry
      • Food & Beverage
      • Healthcare
      • Legal
      • Manufacturing
      • Mining & Metals
      • Pharmaceutical
    • Testimonials
    • Latest News
    • Blogs
    • Awards
    • Contact Us
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    Home » TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit
    Press Release

    TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit

    By Business Leaders ReviewMay 6, 2022

    TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that several key executives will speak at The 3rd Gamma Delta T Therapies Summit, which will take place on July 26-28, 2022 in Boston, MA.

    TC BioPharm will participate in five separate conference sessions

    • Emilio Cosimo, Product Development Manager, will participate in a workshop, “Characterizing Gamma Delta Subsets to Interrogate Function & Therapeutic Application,” on July 26, 2022 at 11am EDT.
    • Dr. Michael Leek, Co-Founder & Executive Chairman, will hold a session, “Gamma Delta T Therapies – From ‘Last Chance’ to Surrogate Front Line Treatment (Vd2),” on July 27, 2022 at 4:30pm EDT.
    • Angela Scott, Co-Founder & COO, will participate in a panel discussion, “Defining a ‘Super-Donor’ & Discussing Cell Source Considerations to Maximize Off-the-Shelf Product Quality,” on July 28, 2022 at 12pm EDT.
    • Dr. Leek will participate in a panel discussion, “Sharing Perspectives on the Application & Attractiveness of Gamma Delta T Therapy in a Competitive Treatment Landscape,” on July 28, 2022 at 12pm EDT.
    • Scott will hold a session, “Developing Allogeneic Manufacturing Processes to Scale GMP-Compliant, Freeze-Thaw Products (Vd2),” on July 28, 2022 at 2:30pm EDT.

    The 3rd Gamma Delta T Therapies Summit will take place in-person for the first time and bring together over 120 leaders in the field. For more information, visit the conference’s website.

    About TC BioPharm (Holdings) PLC

    TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma delta t-cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

    TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia and Phase I trial for ImmuniStim in treatment of Covid patients using the Company’s proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors and a significant IP/patent portfolio in the use of CARs with gamma delta t-cells and owns our manufacturing facility to maintain cost and product quality controls.

    Forward Looking Statements

    This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. We undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to the website of TC BioPharm has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

    Related Posts

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    May 9, 2025

    Adeption offers 50 scholarships for adaptive leadership program

    May 2, 2025

    KBP to Contest Injunction Obtained by Novo Nordisk

    March 3, 2025

    Fcode Labs to Release Pioneering Whitepaper on the Power of AI in Delivering Exceptional Customer Experiences

    February 14, 2025

    Microsoft Dynamics 365: The Undisputed Leader in Gartner’s Magic Quadrant

    January 20, 2025

    Localis 365: the solution that makes tax management simpler in Latin America

    December 13, 2024
    Top Posts

    MIT’s New Tool “SeaSplat” Reveals True Colors of the Ocean in 3D

    May 23, 2025

    GLP-1 and Weight-Loss Drugs May Curb Alcohol Cravings, Study Finds

    May 14, 2025

    RAGEN & StarPO Aim to Tame LLM Instability in Complex Tasks

    April 25, 2025
    Don't Miss

    MIT’s New Tool “SeaSplat” Reveals True Colors of the Ocean in 3D

    May 23, 2025

    Key Highlights Water bends, scatters, and fades light, making underwater scenes appear hazy and color-distorted.…

    GLP-1 and Weight-Loss Drugs May Curb Alcohol Cravings, Study Finds

    May 14, 2025

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    May 9, 2025

    Adeption offers 50 scholarships for adaptive leadership program

    May 2, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About Us
    About Us

    Business Leaders Review is a global print and digital monthly and yearly magazine, which provides a platform to showcase business/tech leaders and their company’s profile from various sectors. Our aim is to publish the c-suite leaders stories.

    We are helping the leaders & readers to showcase their ideas and innovations to the business and tech world in this current market situation along with their awards and achievements. Doing so we hope to leverage thousands of businesses and personnel around the globe.

    Most Popular

    Breaking Barriers: Shelly Castle’s Story of Empowerment and Success

    Adeption offers 50 scholarships for adaptive leadership program

    KBP to Contest Injunction Obtained by Novo Nordisk

    Latest Magazines
    Facebook X (Twitter) LinkedIn Instagram
    • Home
    • Our Clients
    • Technology
    • Industry News
    • Contact Us
    • Privacy Policy
    • Reprints and Permissions
    © 2025 Business Leaders Review LLC | All Rights Reserved | Empowering Communication Globally

    Type above and press Enter to search. Press Esc to cancel.